SIETES :: 93020 citas

Resultados de la búsqueda por CÁNCER DE OVARIO REFINAR BÚSQUEDA

1.

Anónimo. GlaxoSmithKline to acquire Tesaro for $4.16 nillion. DIA Daily 2018:1. [Ref.ID 102859]

2.

Dyer O. Jury awards $4.7bn damages against Johnson & Johnson in talcum cancer case. BMJ 2018;362:k3135. [Ref.ID 102819]

3.

Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, Bunch KJ, Murphy MFG, Sutcliffe AG. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ 2018;362:k2644. [Ref.ID 102818]

4.

Li X, Zhou J. Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102802]

5.

Huo Y-L, Qiao J-M, Gao S. Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2018;84:abril. [Ref.ID 102680]

6.

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017;83:653-63. [Ref.ID 101935]

7.

Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:24 de mayo. [Ref.ID 101602]

8.

Anónimo. FDA approves rucaparib to treat patients with ovarian cancer whose tumors have BRCA mutation. DIA Daily 2016:1. [Ref.ID 101001]

9.

Anónimo. EMA accepts PARP inhibitor niraparib for review. DIA Daily 2016:3. [Ref.ID 100868]

10.

Anónimo. Olaparib significantly delays recurrence of ovarian cancer compared to placebo, clinical trial finds. DIA Daily 2016:6. [Ref.ID 100859]

11.

Anónimo. AstraZeneca withdraws ovarian cancer drug from EMA consideration. DIA Daily 2016:2. [Ref.ID 100693]

12.

Anónimo. FDA to forgo advisory panel for rucaparib. DIA Daily 2016:2. [Ref.ID 100657]

13.

Anónimo. PARP inhibitors show significant promise in treating ovarian cancer. DIA Daily 2016:6. [Ref.ID 100652]

14.

Anónimo. FDA grants expedited review to ovarian cancer drug. DIA Daily 2016:2. [Ref.ID 100591]

15.

Anónimo. Olaparib. Prescrire 2016;36:406-10. [Ref.ID 100541]

16.

Anónimo. Niraparib meets primary endpoint in late-stage clinical trial of recurrent ovarian cancer patients. DIA Daily 2016:1. [Ref.ID 100452]

17.

Anónimo. Five facts about cancer survival in England. BMJ 2016;353:i3314. [Ref.ID 100437]

18.

Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB, ICON6 Collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;387:1066-74. [Ref.ID 100153]

19.

Anónimo. Traitement hormonal substitutif de la ménopause: cancers de l'ovaire. Prescrire 2015;35:671. [Ref.ID 99718]

20.

Anónimo. Bévacizumab et cancer épithélial de l'ovaire résistant aux sels de platine. Prescrire 2015;35:656-7. [Ref.ID 99713]